OXiGENE To Present at BIO Investor Forum on October 11

OXiGENE To Present at BIO Investor Forum on October 11

WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 4, 2007--Regulatory News:

    OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical-stage,
biopharmaceutical company developing novel therapeutics to treat
cancer and eye diseases, announced today that OXiGENE President and
CEO, Dr. Richard Chin, will present at the BIO Investor Forum at the
Palace Hotel in San Francisco on Thursday, October 11, at 10:00 a.m.
PDT / 1:00 p.m. EDT.

    A live and archived webcast of the presentation will be accessible
via the Company's website at www.oxigene.com under the Investor Center
/ Presentations & Conference Calls section.

    About OXiGENE, Inc.

    OXiGENE is a clinical-stage biopharmaceutical company developing
novel therapeutics to treat cancer and eye diseases. The Company's
major focus is developing vascular disrupting agents (VDAs) that
selectively disrupt abnormal blood vessels associated with solid tumor
progression and visual impairment. OXiGENE is dedicated to leveraging
its intellectual property position and therapeutic development
expertise to bring life-extending and -enhancing medicines to
patients.


CONTACT: OXiGENE, Inc.
             Shari Annes, 650-888-0902
             Investor Relations
             sannes@oxigene.com